47 street rouge powder rubor polvo compacto - Resultados de la búsqueda

Cuba - español - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

tagrisso® 40 mg

astrazeneca ab. - osimertinib (eq. a 47,7 mg de mesilato de osimertinib) - comprimido recubierto - 40 mg

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

doxycare 40 mg comprimidos para gatos y perros

ecuphar nv - doxiciclina hiclato - comprimido - doxiciclina hiclato 47,88mg - doxiciclina - perros; gatos

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

framidex 0.47 % + 0,1 % unguento oftalmico

laboratorios lansier s.a.c. - droguerÍa - unguento oftalmico - por dosis g - - dexametasona y antiinfecciosos

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sedanine 35 mg/ml gel oral para perros

floris holding b.v. - acepromazina maleato - gel oral - acepromazina maleato 47,50mg - acepromazina - perros

Unión Europea - español - EMA (European Medicines Agency)

bimzelx

ucb pharma s.a. - bimekizumab - psoriasis - inmunosupresores - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.